Molecular Indicators of Castration-resistant Prostate Cancer
Abstract
Metastatic prostate cancers are commonly treated by agents designed to suppress androgen receptor (AR) signaling mediated by the full-length AR (AR-FL). Why some patients progress rapidly after treatment while others benefit with prolonged remission is an unsolved question. We propose approaches to develop molecular indicators of response and resistance that will enable prediction (before therapy) or early detection (during therapy) of therapeutic benefit. We will test the hypothesis that AR splice variants (AR-Vs) are molecular indicators of castration-resistant prostate cancer (CRPC). During this funding period, we achieved a major milestone by completing experimental phase of the proposed transcriptome sequencing studies, and began the data analysis phase of the project. In addition, we have identified and acquired biopsy specimens that will be required for the proposed in-situ detection methods. We conclude that androgen receptor splice variants can be detected by RNA sequencing in clinical specimens derived from patients with castration-resistant prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA598449
Entities
People
- Betty Diamond
- Jun Luo
Organizations
- Johns Hopkins University